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Background
As of 2010, over 5 million people
worldwide have access to antiretroviral
drugs (ARVs) [1]. With increased access
comes a greater need to monitor and
promote the safety and effectiveness of
these essential medicines. Few resource-
limited countries have all the structures,
systems, or resources necessary to support
medicines safety activities [2,3]. Diverse
international efforts to provide optimal
treatment could be compromised by the
absence of robust strategies and frame-
works for monitoring of inappropriate use,
toxicity, drug-drug interactions, diversion,
and substandard medicines [4]. While
isolated episodes of substandard medica-
tion distribution have been identified and
handled through the involvement of the
World Health Organization (WHO), glob-
al pharmacovigilance is needed to fully
understand the extent of the issue. Loss of
confidence in the safety of ARVs could
lead to poor adherence and the emergence
of drug resistance, reduced demand for
therapy, or inappropriate switching to
more toxic or expensive medicines. A
sustainable pharmacovigilance system can
help achieve comprehensive, safe, and
effective healthcare. Efforts to date have
attempted to address the need for respon-
sive drug safety monitoring systems for
ARVs in resource-limited settings (RLS)
but with varying success. The Forum for
Collaborative HIV Research (Forum) was
asked to use its neutral setting for key
stakeholders from the United Nations and
government agencies, donors, industry,
academia, multilateral organizations, and
implementers to discuss the creation of a
sustainable global pharmacovigilance sys-
tem for ARVs that would be applicable in
RLS. A meeting was convened by the
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ci nceForum on June 11, 2010, that included
relevant stakeholders to discuss barriers to
progress. Stakeholder participants other
than the authors are identified in the
Acknowledgments.
The Issue: Contrasting
Priorities, Values, and Ideas
The Forum meeting participants dis-
cussed their approaches to establishing an
acceptable and sustainable global pharma-
covigilance framework for ARVs and how
these efforts might be harmonized. The
discussions revealed varieties of methods,
opinions, and practices among the stake-
holders. Challenges in integrating these
different approaches and sub-optimal
communication among stakeholders may
have impeded progress in the past. Each of
the values and ideas represent important
technical, cultural, and economic impera-
tives that require mutual understanding
and respect. The meeting participants
agreed that understanding and mutual
respect for others’ priorities and ideas are
the predicate to effective communication,
then follows collaboration, leading to
resolution or compromise and eventual
success. At the Forum meeting, some of
these contrasting values were highlighted:
1. National sovereignty versus regional and
international collaboration
Sovereignty, country ownership, and
building national infrastructure are values
that have governed international collabo-
ration since the founding of the United
Nations. The WHO, the President’s
Emergency Program for AIDS Relief
(PEPFAR), the Global Fund to Fight
AIDS, Tuberculosis and Malaria (Global
Fund), and the Uppsala Monitoring Cen-
ter/WHO Collaborating Centre for Inter-
national Drug Monitoring (UMC) all
value national sovereignty. Their remit
has been to work with national systems
wherever possible. They also recognize
that the need for data sharing and
resource efficiency in some cases is best
done through collaboration among region-
al and international stakeholders who
provide systems, expert personnel, and
other resources.
2. The value of pharmacovigilance versus the
needs for care delivery
Optimal use of all available resources to
deliver safe and effective HIV treatment
and prevention is a priority. Safe and
effective use of medicines is only guaran-
teed when access goes hand-in-hand with
pharmacovigilance. Many stakeholders
perceive the cost of pharmacovigilance
infrastructure as competing with distribu-
tion of scarce human and financial re-
sources for direct care delivery. This
perception may impede the devotion of
time and resources to development of
sustainable global pharmacovigilance.
3. Research, pharmacovigilance, and program-
matic funding
Scarce funds are distributed through
diverse channels whose distinctions may
be artificial in the resource-limited world.
Established health care systems have
separate channels for funding for research,
pharmacovigilance, and operations. Re-
search monies are mainly derived from
national scientific or medical agencies,
industry research, and foundations. Phar-
macovigilance is largely funded by the
operational side of the pharmaceutical
industry and by health ministries. Health
care operations are funded by insurance
companies, donors, and national health
systems. The absence of global pharma-
covigilance systems, the need to develop
systems that may differ from well-estab-
lished models, and the need to assess the
feasibility of novel models offer opportu-
nities for innovation. Barriers among these
channels of funding in established systems
are not applicable in RLS. Sustainable
global pharmacovigilance must derive
support from operational, research, and
programmatic funds as programs, such as
health care delivery and pharmacovigi-
lance, are inextricably intertwined in this
setting with the need for epidemiological
and implementation research [5].
4. Active versus spontaneous surveillance
Active surveillance with intensive data
collection is one proven method of sys-
tematically identifying and assessing med-
ication use and patient outcomes. Sponta-
neous surveillance collects reporters’
concerns about an event seen during
treatment, assesses clinical causality, and
provides timely information on low inci-
dence adverse events that manifest upon
exposure of large numbers of patients to
drug products. Spontaneous reporting can
be time consuming and adds to the
workload of already overburdened health-
care professionals in RLS. In these in-
stances, monitoring through a sentinel site
might be a viable alternative. Active
surveillance of cohorts [6] or through the
use of registries (e.g., the established
Antiretroviral Pregnancy Registry) [7]
may be more expensive but provides a
mechanism for assessing incidence and to
conduct pharmacovigilance within special
populations. While countries with estab-
lished pharmacovigilance can employ both
systems effectively, the best mix for RLS
still requires careful planning.
5. Confidentiality of safety data versus need for
transparency and public access
Regulatory agencies in Europe receive
confidential safety data from pharmaceu-
tical companies for registration purposes
and afterwards in post-marketing surveil-
lance. Confidentiality may be important to
assure that adverse event relationships that
are later understood to be associative
rather than causative do not create undue
public confusion or alarm. But, interna-
tional data sharing is necessary to support
global pharmacovigilance, particularly giv-
en international trade and traffic in
pharmaceuticals.
6. Industry support versus global enforcement of
reliable reporting
The pharmaceutical industry plays an
active role in funding pharmacovigilance
in many nations. In respect of national
sovereignty and, possibly, to avoid indus-
try conflicts of interest in reporting events
that may undermine investor confidence,
Summary Points
N With increasing numbers of people worldwide on antiretroviral drugs, the need
for improved and sustained global drug safety monitoring or pharmacovigi-
lance is critical.
N Pharmacovigilance includes monitoring for substandard products, diversion,
inappropriate use, and toxicity and is an essential component of safe and
effective drug usage.
N The Forum for Collaborative HIV Research was asked to use its neutral setting
for key stakeholders from the UN and government agencies, donors, industry,
academia, multilateral organizations, and implementers to discuss the creation
of a sustainable global pharmacovigilance system for ARVs.
N Important but contrasting priorities and values among stakeholders—all of
whom are dedicated to establishing global pharmacovigilance—were identified
as barriers to progress.
N Recognition, understanding, and respect for these contrasts is a pathway for
increased collaboration and cooperation that will then lead to a sustainable
system involving all stakeholders including industry and experienced regulatory
agencies.
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not drawn upon industry funding and
collaboration. In countries with estab-
lished drug regulation, the conflict is partly
controlled by audit, laws, regulations, and
enforcement—a system not necessarily
available globally. A global system that
enjoys reliable industry engagement must
draw upon new or shared sources for
funding of enforcement.
7. Generic versus innovator antiretroviral
manufacturers
Generic companies provide a significant
proportion of ARVs distributed in RLS.
The lower pricing ensures greater access
[8]. But, correspondingly, these companies
may devote fewer resources for pharma-
covigilance. Established systems rely upon
innovator companies to support pharma-
covigilance on market entry, but this may
not work in RLS where innovator com-
panies may not be marketing their com-
pounds.
Progress
There has been great progress in
international identification of the need for
collaboration and renewed vigor in pursu-
ing a global pharmacovigilance system—
an important outcome of the Forum
meeting. This is reflected in recent and
ongoing developments in intergovernmen-
tal assistance programs as well as initiation
support from the WHO and allied inter-
national and national entities. The Fo-
rum’s meeting recognized ongoing efforts
for collaborative pharmacovigilance
among less resource-rich nations. In No-
vember 2009, a WHO-Global Fund
Pharmacovigilance Strategy was drafted
that identified the elements and roadmap
for a sustainable, global partnership for
system-driven pharmacovigilance [9]. The
concept paper together with the minimum
pharmacovigilance requirements for coun-
tries in RLS were presented for consider-
ation at a Pharmacovigilance Stakeholders
Meeting in November 2010, in Accra,
Ghana. Participants included many of
those present at the Forum meeting and
were invited to comment. Progress was
made on encouraging regional systems
and the inclusion of international resourc-
es [10,11]. There was support for the
continued development of UMC as a
global resource for pharmacovigilance
activities.
The US Agency for International De-
velopment (USAID)-funded Strengthening
Pharmaceutical Systems (SPS) program
implemented by Management Sciences
for Health sponsored a conference in
Nairobi, Kenya, entitled ‘‘National Phar-
macovigilance Systems: Ensuring the Safe
Use of Medicines,’’ on the implementation
of pharmacovigilance systems from a
country-centered perspective. The confer-
ees discussed a framework for pharmacov-
igilance and the need for performance
metrics—the Indicator-based Pharmacov-
igilance Assessment Tool (IPAT)—and
experiences and best practices were shared
by participants from 30 countries.
The first version of a Web-based
‘‘Pharmacovigilance Toolkit,’’ developed
by the WHO Collaborating Centre for
Advocacy and Training in pharmacovigi-
lance (the WHO CC/UMC-Africa) along
with SPS and other partners, was present-
ed at the Stakeholders meeting in Accra
[12].
More recently, WHO has initiated two
major projects in pharmacovigilance with
the support of the Bill & Melinda Gates
Foundation (BMGF). A pilot sentinel
cohort in Tanzania established with the
collaboration of UMC and the national
health ministry may be open to patient
enrollment soon. Second, the US National
Institute of Allergy and Infectious Diseases
(NIAID) is working collaboratively with
WHO to establish spontaneous adverse
event reporting in their IeDEA patient
cohorts in two countries with an aim of
evaluating and improving an abbreviated
reporting system developed by UMC
(CEMFlow). The Global Fund has also
supported a start-up pharmacovigilance
program for ARVs in the Ukraine.
Monitoring Medicines, a project funded
by the European Commission, brings
together 11 partners, including WHO,
the UMC, and the Copenhagen HIV
Programme, to advance pharmacovigi-
lance within and outside the European
Union (EU) [13]. The 14 work packages
within this project consider various issues
such as tools to support public reporting of
adverse drug reactions; an electronic
platform that consolidates HIV ADR
information from several sources (http://
www.hivpv.org/); and an algorithm for
the detection of substandard and counter-
feit medicines from pharmacovigilance
data.
Finally, the US National Institutes of
Health, the Global Fund, UMC, and a
consortium of North American universities
led by the University of Indiana (funded
by PEPFAR through USAID) have col-
laboratively initiated a pharmacovigilance
program with the Kenyan national health
ministry. This illustrates, as well, the
growing number of academic institutions
that are engaged in pharmacovigilance:
advancing methods, creating an evidence-
base for assessing and improving medi-
cines safety, performing statistical and data
analyses, and training practitioners.
Much Remains to Be Done
More can be achieved. Principally,
there is hope for more inclusion of non-
national stakeholders and experienced
regulators and, perhaps more importantly,
for assurance of financial and institutional
sustainability. Many stakeholders with
substantial interests are still not routinely
at the table. Most prominently, the
pharmaceutical industry, both innovator
and generic, are not included, although
both sets of institutions have substantial
investment in global infrastructure, per-
sonnel, data management, databases, and
other resources that could be purposed, at
least in part, to sustaining global pharma-
covigilance systems in RLS. Well-estab-
lished national regulatory authorities, such
as the European Medicines Agency
(EMA), the US Food and Drug Adminis-
tration (FDA), and the WHO Prequalifi-
cation Programme also have data, exper-
tise, human resources, and technical
capacity that could be used more system-
atically to support pharmacovigilance in
RLS. The EU has provided research and
development money for pharmacovigi-
lance. This funding must be continued in
future rounds of EU funding. More
transparent and proactive mechanisms
for drug evaluation at all national regula-
tory agencies may also enhance support
for comprehensive and sustainable phar-
macovigilance. Those mechanisms may
also raise awareness of the importance of
pharmacovigilance.
Current projects need sustainable, if not
growing, support. BMGF research funding
will largely end in 2012. Round 11 of the
Global Fund is unlikely to result in
initiation of new pharmacovigilance pro-
grams. PEPFAR currently supports the
clinical care and treatment of over 3.2
million people and has funded the
strengthening of supply chains and access
to pharmaceuticals. PEPFAR also sup-
ports some WHO pharmacovigilance ac-
tivities but is also exploring ways to
collaboratively fund pharmacovigilance
systems to further strengthen the quality
of national HIV programs. National laws,
remits of international agencies, and
funding authorizations may need to spe-
cifically address the need for funding of
sustainable global pharmacovigilance.
Still, too little is understood about the
value and need for global pharmacovigi-
lance and more must be done among
funding organizations, including national
bodies in resource-rich nations with
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tween disease-driven national programs
(e.g., HIV/AIDS) and national pharma-
covigilance centers should be made. While
BMGF and NIAID have provided re-
search funding, barriers between the
purpose of those funds and investigations
into sustainable systems and funding for
those systems remain. Decisions on fund-
ing must include participation and collab-
oration with academic researchers, indus-
try, donors, and well-resourced existing
pharmacovigilance systems. Pharmaceuti-
cal industry resources must be more
effectively recruited and used in imple-
mentation, whether in terms of interna-
tional and national mandates or in terms
of in-kind technical support.
Stakeholder collaboration, communica-
tion, and joint activity are developing
rapidly. Stakeholders must continue to
work together and communicate. There
must be a formalized process comparable
to the Forum-initiated consortium to
ensure ongoing communication among
all stakeholders that includes established
national regulators and the innovator and
generic companies. A workable system will
not be necessarily based on each resource-
limited national entity or regional pro-
gram developing a separate system—there
are simply insufficient technical, manage-
ment, and funding resources. Instead, the
stakeholders must collaboratively insist on
broader systems that provide local value.
These systems should be highly valued and
be supported by industry, governments
and funders of HIV programs and nation-
al health systems, multilateral organiza-
tions, and other key stakeholders, and
should be funded even during difficult
economic times.
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